Figure 7.

Kaplan-Meier overall survival according to CTCs. (A) Patients with metastatic prostate cancer (PCa-m) with ≥5 CTCs and <5 CTCs showed differences in OS (27.5 months vs. 37 months [HR 2.6, 95% CI, 0.78–8.3]). (B) CTC kinetics for PCa-m patients with ≥5 CTCs at all-time points; the median OS differed between those with declining CTC (↓≥5 CTCs) counts and those with increasing CTC (↑≥5 CTCs) counts (25 months vs. 34 months, HR 1.9, 95% CI, 0.4–11.6). HR, hazard ratio; OS, overall survival; CTCs, circulating tumor cells.